{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:44:47Z","timestamp":1760298287165},"reference-count":9,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":9763,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Scandinavian Journal of Haematology"],"published-print":{"date-parts":[[1982,8]]},"abstract":"<jats:p>17 patients (age 15\u201358 years) with refractory acute leukaemia (14 AML, 3 ALL) were treated with high dose cytosine arabinoside (AraC) at a dose of 3000 mg\/m<jats:sup>2<\/jats:sup>, twice daily for 6 d (13 patients with AraC alone, 4 patients with AraC and doxorubicin). 9 patients achieved complete remission (53 %) and 2 a partial remission. Although sophisticated isolation and blood banking facilities are required during the pancytopenic period, the toxicity of this treatment was acceptable. Vomiting, headache, somnolence, fever, conjunctivitis and cardiac arrhythmias were found most frequently. The unexpected pulmonary failure in 3 patients was worrisome. The duration of remissions was from 1 to 12 months.<\/jats:p><jats:p>Results obtained with high dose AraC are satisfactory and hold promise for the treatment of patients with previously untreated AML.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1982.tb00575.x","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T15:39:22Z","timestamp":1280936362000},"page":"141-146","source":"Crossref","is-referenced-by-count":59,"title":["High Dose Cytosine Arabinoside in the Management of Refractory Acute Leukaemia"],"prefix":"10.1111","volume":"29","author":[{"given":"R.","family":"Willemze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. E.","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Colpin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Keuning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_1","unstructured":"CollyL.(1980)Chemotherapy in a transplantable myeloid leukemia in brown Norway rats.Thesis University of Leyden Holland."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197808)42:2 <874::AID-CNCR2820420709>3.0.CO;2-O"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/143.5.644"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(81)90759-2"},{"key":"e_1_2_1_6_1","first-page":"191a","article-title":"High dose cytosine arabinoside in the treatment of patients with refractory acute non\u2010lymphocytic leukemia.","volume":"54","author":"Karanes C.","year":"1979","journal-title":"Blood"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6107.199"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197910)44:4<1189::AID-CNCR2820440404>3.0.CO;2-O"},{"key":"e_1_2_1_9_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/archinte.1974.00320140089009","article-title":"Cytarabine for acute leukemia in adults","volume":"133","author":"South West Oncology Group","year":"1974","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.V46.6.823.823","article-title":"Treatment of acute lymphoblastic leukemia in adolescents and adults: a retrospective study of 41 patients (1970\u20131973)","volume":"46","author":"Willemze R.","year":"1975","journal-title":"Blood"}],"container-title":["Scandinavian Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1982.tb00575.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1982.tb00575.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T11:20:32Z","timestamp":1699442432000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1982.tb00575.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,8]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1982,8]]}},"alternative-id":["10.1111\/j.1600-0609.1982.tb00575.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1982.tb00575.x","archive":["Portico"],"relation":{},"ISSN":["0036-553X"],"issn-type":[{"value":"0036-553X","type":"print"}],"subject":[],"published":{"date-parts":[[1982,8]]}}}